From a clinical point of view, our results provide strong support for the use of bispecific antibody anti-EGFR/anti-FcγRIIIA as a novel strategy of antitumor immunotherapy to improve the ADCC-mediated efficiency of cetuximab in recruiting FcγRIIIA+ (CD16) ADCC effector cells at tumor site and offering an effective linkage between drugs and tumor target. Here, FCGR3A is linked to neoplasm.